Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRecurv Pharma Inc
About this trial
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
Eligibility criteria
Qualifiers
Phase 1: Participants with solid tumors who are candidates for treatment with a taxane
Phase 2a: Participants with relapsed or refractory PDAC, or CRC.
Disqualifiers
1. Active infection requiring systemic anti-infective therapy within 28 days prior to first dose of RP-001.
Trial design
Treatments tested in this trial
- RP-001
Treatment groups
66 Participants
are divided into 5 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov